Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q4EQ
|
||||
| Former ID |
DIB015332
|
||||
| Drug Name |
JNJ-38158471
|
||||
| Synonyms |
JNJ-38158471; VEGFR-2 inhibitors (angiogenesis disorder/cancer); VEGFR-2 inhibitors (angiogenesis disorder/cancer), Johnson & Johnson
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Angiogenesis disorder [ICD10:I00-I99] | Investigative | [543499] | ||
| Company |
Johnson & Johnson
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H17ClN6O3
|
||||
| Canonical SMILES |
n1cnc(c(c1N)/C=N/OC)Oc1cc(c(cc1)NC(=O)NCC)Cl
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Inhibitor | [543499] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.